Safety and immunogenicity of 26-valent group a streptococcus vaccine in healthy adult volunteers
- PMID: 16163629
- DOI: 10.1086/444458
Safety and immunogenicity of 26-valent group a streptococcus vaccine in healthy adult volunteers
Abstract
Background: Group A streptococcus (GAS) causes illness ranging from uncomplicated pharyngitis to life-threatening necrotizing fasciitis, toxic shock, and rheumatic fever. Attempts to develop an M protein-based vaccine have been hindered by the fact that some M proteins elicit both protective antibodies and antibodies that cross-react with human tissues. New molecular techniques have allowed the previous obstacles to be largely overcome.
Methods: The vaccine is comprised of 4 recombinant proteins adsorbed to aluminum hydroxide that contain N-terminal peptides from streptococcal protective antigen and M proteins of 26 common pharyngitis, invasive, and/or rheumatogenic serotypes. Thirty healthy adult subjects received intramuscular 26-valent GAS vaccine (400 microg) at 0, 1, and 4 months, with clinical and laboratory follow-up for safety and immunogenicity using assays for tissue cross-reactive antibodies, type-specific M antibodies to 27 vaccine antigens, and functional (opsonization) activity of M protein antibodies.
Results: The incidence of local reactogenicity was similar to that for other aluminum hydroxide-adsorbed vaccines in adults. No subject developed evidence of rheumatogenicity or nephritogenicity, and no induction of human tissue-reactive antibodies was detected. Overall, 26 of 27 antigenic peptides evoked a >4-fold increase in the geometric mean antibody titer over baseline. The mean log2 fold-increase in serum antibody titer (+/- standard error of the mean) for all 27 antigens was 3.67 +/- 0.21. A significant mean log2 reduction in streptococcal bacterial counts in serum samples obtained after immunization was seen in opsonization assays for all M serotypes.
Conclusions: On the basis of epidemiological data demonstrating that the majority of cases of pharyngitis, necrotizing fasciitis, and other invasive streptococcal infections are caused by a limited number of serotypes, this 26-valent vaccine could have significant impact on the overall burden of streptococcal disease.
Comment in
-
Immunity to group a streptococcal M proteins: forging a single-edged sword.Clin Infect Dis. 2005 Oct 15;41(8):1123-4. doi: 10.1086/444465. Epub 2005 Sep 12. Clin Infect Dis. 2005. PMID: 16163630 No abstract available.
Similar articles
-
Safety and immunogenicity of a 30-valent M protein-based group a streptococcal vaccine in healthy adult volunteers: A randomized, controlled phase I study.Vaccine. 2020 Feb 5;38(6):1384-1392. doi: 10.1016/j.vaccine.2019.12.005. Epub 2019 Dec 13. Vaccine. 2020. PMID: 31843270 Clinical Trial.
-
Safety and immunogenicity of a recombinant multivalent group a streptococcal vaccine in healthy adults: phase 1 trial.JAMA. 2004 Aug 11;292(6):709-15. doi: 10.1001/jama.292.6.709. JAMA. 2004. PMID: 15304468 Clinical Trial.
-
Intranasal administration is an effective mucosal vaccine delivery route for self-adjuvanting lipid core peptides targeting the group A streptococcal M protein.J Infect Dis. 2006 Aug 1;194(3):316-24. doi: 10.1086/505580. Epub 2006 Jun 30. J Infect Dis. 2006. PMID: 16826479
-
Prospects for a group A streptococcal vaccine.Curr Opin Mol Ther. 2005 Feb;7(1):11-6. Curr Opin Mol Ther. 2005. PMID: 15732524 Review.
-
Differences among group A streptococcus epidemiological landscapes: consequences for M protein-based vaccines?Expert Rev Vaccines. 2009 Dec;8(12):1705-20. doi: 10.1586/erv.09.133. Expert Rev Vaccines. 2009. PMID: 19905872 Review.
Cited by
-
Correlates of Protection for M Protein-Based Vaccines against Group A Streptococcus.J Immunol Res. 2015;2015:167089. doi: 10.1155/2015/167089. Epub 2015 May 25. J Immunol Res. 2015. PMID: 26101780 Free PMC article. Review.
-
Immunotherapy targeting the Streptococcus pyogenes M protein or streptolysin O to treat or prevent influenza A superinfection.PLoS One. 2020 Jun 23;15(6):e0235139. doi: 10.1371/journal.pone.0235139. eCollection 2020. PLoS One. 2020. PMID: 32574205 Free PMC article.
-
emm and C-repeat region molecular typing of beta-hemolytic Streptococci in a tropical country: implications for vaccine development.J Clin Microbiol. 2009 Aug;47(8):2502-9. doi: 10.1128/JCM.00312-09. Epub 2009 Jun 10. J Clin Microbiol. 2009. PMID: 19515838 Free PMC article.
-
Prospective surveillance of invasive group a streptococcal disease, Fiji, 2005-2007.Emerg Infect Dis. 2009 Feb;15(2):216-22. doi: 10.3201/eid1502.080558. Emerg Infect Dis. 2009. PMID: 19193265 Free PMC article.
-
Detection of serum p53 antibodies from Chinese patients with papillary thyroid carcinoma using phage-SP-ELISA: correlation with clinical parameters.Endocrine. 2014 Nov;47(2):543-9. doi: 10.1007/s12020-014-0243-9. Epub 2014 Mar 30. Endocrine. 2014. PMID: 24682740
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical